Locket No.: B45198

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Combined Vaccine Compositions

| | 7 September 2000 as Seri | | |
|---|---|--|---|
| and was amended | on (if a | applicable). | |
| | reviewed and understand ny amendment referred to | | dentified specification, including the |
| I acknowledge the duty to of Federal Regulations, | | nich is material to the paten | tability as defined in Title 37, Code |
| I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. | | | |
| Prior Foreign Application | on(s) | | |
| Number | Country | Filing Date | Priority Claimed |
| GB 9921146.8 | Great Britain | 07 September 1999 | Yes |
| I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below. | | | |
| Application Number | Filing Date | | |
| Section 365(c) of any P subject matter of each of International application 112, I acknowledge the of Federal Regulations, | CT International application of the claims of this applic in in the manner provided duty to disclose information. | ion designating the United action is not disclosed in the by the first paragraph of Ti ion which is material to particle available between the first | of any United States application(s) or States, listed below and, insofar as the prior United States or PCT itle 35, United States Code, Section tentability as defined in Title 37, Code illing date of the prior application and |
| Serial No. | Filing Date | Status | |

A Mereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to Zoltan Kerekes, GlaxoSmithKline, Corporate Intellectual Proprety-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5024.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Martine Anne Cecile WETTENDORFF

Residence: Rixensart, Belgium

Citizenship:

Post Office Address: GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939